Scientists identify new target for developing precision treatment in malignant brain tumors

January 31, 2018 by Ashley J Wennersherron, Virginia Tech
Kevin Pridham (left), a doctoral student in Virginia Tech's translational biology, medicine, and health graduate program, and Zhi Sheng, an assistant professor at the Virginia Tech Carilion Research Institute, have identified a new therapeutic target to treat glioblastoma, the most devastating and common form of brain cancer. Credit: Virginia Tech

A Virginia Tech Carilion Research Institute team has identified a new therapeutic target to treat glioblastoma, the most devastating and common form of brain cancer.

The disease most recently made national headlines last year when Sen. John McCain of Arizona announced his glioblastoma diagnosis in July. Before that, Sen. Ted Kennedy, of Massachusetts, and former Vice President Joe Biden's son, Beau Biden, both died after battling against glioblastoma.

The scientists published their results in Neuro-Oncology and further contextualized their work in a review paper published in Frontiers in Oncology.

"Patients with glioblastoma survive for less than 15 months from diagnosis on average, even following brain surgery to remove the , radiation therapy, and chemotherapy," said Zhi Sheng, an assistant professor at the VTCRI and senior author on both papers. "More than 90 percent of the who survive more than two years after their first treatments develop tumor recurrence. Unfortunately, these patients are often not eligible for a second brain surgery, and the recurrent tumors become resistant to chemotherapy and radiation."

Currently, no standard of care exists to prevent or treat recurrent malignant primary brain tumors in patients.

"It is imperative to find effective treatments for ," said Sheng, who is also an assistant professor of biomedical sciences and pathobiology at the Virginia-Maryland College of Veterinary Medicine.

Sheng and his team previously identified 20 genes that are important for to persist. From those genes, they found a particular class responsible for coding proteins that regulate how cellular signaling pathways transmit external messages into the cells. The level of these proteins can be used as biomarkers for predicting the occurrence and prognosis of recurrent glioblastoma.

"Our research demonstrates that patients with glioblastoma who have a greater chance of tumor recurrence often express this class of genes and proteins at high levels," Sheng said.

Patients could potentially have their protein levels screened to help predict their risk for recurrent glioblastoma. The protein not only indicates risk for recurrent tumors, but scientists can also target it to potentially treat or even prevent subsequent tumors.

Sheng and his team found that a subunit of this gene class, named PIK3C-beta, along with a protein product called p110-beta, are critical for glioblastoma cell survival. The researchers used a molecule to inhibit the expression of this particular protein, stopping p110-beta from communicating necessary information downstream. Without the signals emanating from this protein, the cancer cells started to die off.

"By selectively targeting PIK3C-beta/p110-beta, we were able to suppress the viability and growth of glioblastoma cells in a mouse model," said Kevin Pridham, a doctoral student in Virginia Tech's translational biology, medicine, and health graduate program. Pridham, who is conducting his dissertation research in Sheng's laboratory, was first author on both papers.

According to Pridham, inhibiting the not only reduced the survival of glioblastoma cells, it also proved less toxic than traditional chemotherapy to healthy brain cells.

"The chemical inhibitor of PIK3C-beta/p110-beta proved modestly effective by itself," Pridham said. "Next, we need to test the effect of the inhibitor in combination with other therapies, such as chemotherapy and radiation."

By further developing this approach, researchers could theoretically design a precise treatment for a person with elevated levels of PIK3C-beta/p110-beta, in conjunction with more traditional treatments such as chemotherapy and radiation.

"Precision medicine is the future for treating patients with glioblastoma," Sheng said. "The research presented in these papers sets a preclinical stage for future development of precise treatment for patients with a higher chance of ."

Scientists need to completely understand the full range of variables that influence glioblastoma development, including patient factors such as tumor stage, to more precisely develop this therapeutic strategy. But it's a step forward, according to Sheng.

"This approach offers hope for a strategy that may be able to improve the prognosis and quality of life for patients," Sheng said.

Explore further: Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

More information: Kevin J. Pridham et al. The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma, Frontiers in Oncology (2017). DOI: 10.3389/fonc.2017.00312

Kevin J Pridham et al. PIK3CB/p110β is a selective survival factor for glioblastoma, Neuro-Oncology (2017). DOI: 10.1093/neuonc/nox181

Related Stories

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Combination chemotherapy may significantly improve treatment for deadly brain tumor

January 22, 2018
A diagnosis of the brain cancer glioblastoma carries a dismal prognosis, with most patients dying within five years. Now a team led by Massachusetts General Hospital (MGH) investigators has found that adding the chemotherapy ...

Identification of PTPRZ as a drug target for cancer stem cells in glioblastoma

July 19, 2017
Glioblastoma is a malignant brain tumor with high mortality. Cancer stem cells are thought to be crucial for tumor initiation and its recurrence after standard therapy with radiation and temozolomide (TMZ) chemotherapy. Protein ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Vulnerability identified for subtypes of glioblastoma

November 30, 2017
Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University ...

DNA becomes primary target in fight against glioblastoma

July 21, 2017
By exploiting a brain tumor's own biology, researchers at FIU's Biomolecular Sciences Institute (BSI) are hoping to destroy glioblastoma, a deadly brain cancer with no known cure.

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.